Licarbazepine
{{Short description|Active metabolite of oxcarbazepine}}
{{Drugbox
| IUPAC_name = (RS)-10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide
| image = Licarbazepine.svg
| width = 170
| caption = Top: (R)-(−)-licarbazepine
Bottom: (S)-(+)-licarbazepine
| drug_name =
| chirality = Racemic mixture
| tradename =
| licence_EU =
| licence_US =
| DailyMedID =
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category =
| legal_AU =
| legal_CA =
| legal_UK =
| legal_US =
| legal_status =
| dependency_liability =
| routes_of_administration =
| bioavailability =
| protein_bound = <40%
| metabolism =
| metabolites = Glucuronides
| elimination_half-life =
| excretion = Mainly renal
| CAS_number = 29331-92-8
| CAS_supplemental =
| ATCvet =
| ATC_prefix = None
| ATC_suffix =
| ATC_supplemental =
| PubChem = 114709
| PubChemSubstance =
| IUPHAR_ligand =
| DrugBank =
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = XFX1A5KJ3V
| ChEMBL = 1067
| ChemSpiderID = 102704
| KEGG = D09215
| chemical_formula =
| C=15 | H=14 | N=2 | O=2
| smiles = NC(=O)N1c2ccccc2CC(O)c3ccccc13
| StdInChI = 1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)
| StdInChIKey = BMPDWHIDQYTSHX-UHFFFAOYSA-N
| synonyms =
| density =
| melting_point =
| melting_high =
| melting_notes =
| boiling_point =
| boiling_notes =
| solubility =
| specific_rotation =
| sec_combustion =
}}
Licarbazepine is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects that is related to oxcarbazepine.{{cite journal | vauthors = Singh RP, Asconapé JJ | title = A review of eslicarbazepine acetate for the adjunctive treatment of partial-onset epilepsy | journal = Journal of Central Nervous System Disease | volume = 3 | pages = 179–87 | year = 2011 | pmid = 23861647 | pmc = 3663619 | doi = 10.4137/JCNSD.S4888 }} It is an active metabolite of oxcarbazepine.{{cite journal | vauthors = Bialer M, Soares-da-Silva P | title = Pharmacokinetics and drug interactions of eslicarbazepine acetate | journal = Epilepsia | volume = 53 | issue = 6 | pages = 935–46 | date = June 2012 | pmid = 22612290 | doi = 10.1111/j.1528-1167.2012.03519.x | s2cid = 21233948 | doi-access = free }} In addition, an enantiomer of licarbazepine, eslicarbazepine ((S)-(+)-licarbazepine), is an active metabolite of eslicarbazepine acetate. Oxcarbazepine and eslicarbazepine acetate are inactive on their own, and behave instead as prodrugs to licarbazepine and eslicarbazepine, respectively, to produce their therapeutic effects.
References
{{Reflist|2}}
{{Anticonvulsants}}
{{Mood stabilizers}}
{{Neuropathic pain and fibromyalgia pharmacotherapies}}
{{Channel blockers}}
{{Tricyclics}}
Category:Human drug metabolites
{{anticonvulsant-stub}}